Trial in Metastatic Colorectal Cancer With FOLFIRI Plus Aflibercept as First Line Treatment
Status:
Unknown status
Trial end date:
2019-03-01
Target enrollment:
Participant gender:
Summary
Investigators propose to study the combination of m FOLFIRI plus Aflibercept in a Phase II
trial of patients with metastatic colorectal cancer. The promising results of aflibercept
derived from preclinical studies and from clinical trials conducted in patients with
refractory of recurrent to oxaliplatin-based 1st line treatment in patients with mCRC open
the field to explore such therapeutic approaches in the 1st line setting in combination with
the FOLFIRI regimen.